Effect of Aging, Glucose Level, and HIV Viral Load on Response to Treatment with Pegylated Interferon Plus Ribavirin in HIV/HCV Co-Infected Women

Autor: Paola Nasta, Giampiero Carosi, Massimo Puoti, Gabriella Verucchi, Ivana Maida, E. Angeli, Emanuele Pontali, Claudio Iannacone, Anna Maria Cattelan, Mariarosaria Giralda, Antonietta Caputo
Přispěvatelé: Nasta, P, Maida, I, Cattelan, Am, Pontali, E, Angeli, E, Giralda, M, Verucchi, G, Caputo, A, Iannacone, C, Puoti, M, Carosi, G.
Rok vydání: 2015
Předmět:
Adult
Male
Oncology
Aging
medicine.medical_specialty
Time Factors
Treatment outcome
HIV Infections
Hepacivirus
Interferon alpha-2
Logistic regression
Antiviral Agents
Polyethylene Glycols
Therapy naive
Virological response
chemistry.chemical_compound
Pegylated interferon
Internal medicine
Ribavirin
medicine
Humans
HIV Infections -- Drug Therapy Hepatitis C -- Drug Therapy Comorbidity Age Factors Blood Glucose -- Metabolism Viral Load Interferons -- Therapeutic Use Ribavirin -- Therapeutic Use Treatment Outcomes
Coinfection
business.industry
Interferon-alpha
virus diseases
General Medicine
Hepatitis C
Chronic
Middle Aged
Viral Load
Response to treatment
Recombinant Proteins
Glucose
Logistic Models
Treatment Outcome
Italy
chemistry
Immunology
HIV-1
RNA
Viral
Drug Therapy
Combination
Female
business
Viral load
medicine.drug
Zdroj: Journal of Women's Health. 24:159-164
ISSN: 1931-843X
1540-9996
Popis: BACKGROUND: This was a post-hoc analysis of the Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study, originally designed to document routine clinical and treatment data in HIV/HCV coinfected patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV). The aim of this study was to define the impact of several variables, such as age, glucose metabolism, and HIV viral load, on PEG-IFN/RBV treatment outcomes, in HIV/HCV coinfected women. METHODS: Female subjects from the OPERA database were retrospectively evaluated and factors associated with sustained virological response (SVR) were assessed and compared to the male population by logistic regression analysis. At baseline, clinical and demographic data were collected. Patients were then administered with PEG-IFN/RBV therapy for 48 weeks. After a 24-week follow-up period, SVR was evaluated. RESULTS: A total of 1523 patients were enrolled in 98 centers across Italy, 1284 of whom were IFN therapy naïve and were included in the post-hoc analysis. In the female group, factors associated with SVR were the presence of HCV genotype 2,3 (adjusted odds ratio [AOR]=6.87, p
Databáze: OpenAIRE
Externí odkaz: